Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 91, Issue -, Pages 109-124Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2015.02.005
Keywords
Albumin; Immunoglobulin G; FcRn; Nanoparticle; Protein engineering
Categories
Funding
- National Institutes of Health (NIH) [R21 EB015520]
- NIH training grant [T32 GM007175]
- American Foundation for Pharmaceutical Education (AFPE)
- UCSF Graduate Dean's Chancellor's Fellowship
- Pharmaceutical Research and Manufacturers of America (PhRMA) foundation
- Stanford Molecular and Cellular Immunobiology NIH postdoctoral training grant [5T32 AI072905]
Ask authors/readers for more resources
Immunoglobulin G (IgG)-based drugs are arguably the most successful class of protein therapeutics due in part to their remarkably long blood circulation. This arises from IgG interaction with the neonatal Fc receptor, FcRn. FcRn is the central regulator of IgG and albumin homeostasis throughout life and is increasingly being recognized as an important player in autoimmune disease, mucosal immunity, and tumor immune surveillance. Various engineering approaches that hijack or disrupt the FcRn-mediated transport pathway have been devised to develop longlasting and non-invasive protein therapeutics, protein subunit vaccines, and therapeutics for treatment of autoimmune and infectious disease. In this review, we highlight the diverse biological functions of FcRn, emerging therapeutic opportunities, as well as the associated challenges of targeting FcRn for drug delivery and disease therapy. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available